PMID- 12499468
OWN - NLM
STAT- MEDLINE
DCOM- 20030114
LR  - 20190514
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 59
IP  - 12 Suppl 6
DP  - 2002 Dec 24
TI  - Composition and properties of IVIg preparations that affect tolerability and 
      therapeutic efficacy.
PG  - S28-32
AB  - The use of intravenous immune globulin (IVIg) has increased significantly in the 
      past decade, benefiting a wide variety of immune diseases. Seven different 
      formulations of IVIg are now licensed in the United States. Although all contain 
      pooled IgG, there are differences in their production and composition that affect 
      their efficacy, tolerability, and side-effect profile. Important variables 
      include concentration, volume, osmolality, sodium, and sugar content. This 
      article reviews what is known about the composition and properties of the various 
      IVIg formulations that might affect the therapeutic outcome.
FAU - Lemm, Georg
AU  - Lemm G
AD  - Bayer Corporation, Research Triangle Park, NC 27709, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Autoimmune Diseases of the Nervous System/*drug 
      therapy/immunology/physiopathology
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Tolerance/physiology
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Pharmaceutical Preparations/*administration & dosage
MH  - Treatment Outcome
RF  - 25
EDAT- 2002/12/25 04:00
MHDA- 2003/01/15 04:00
CRDT- 2002/12/25 04:00
PHST- 2002/12/25 04:00 [pubmed]
PHST- 2003/01/15 04:00 [medline]
PHST- 2002/12/25 04:00 [entrez]
AID - 10.1212/wnl.59.12_suppl_6.s28 [doi]
PST - ppublish
SO  - Neurology. 2002 Dec 24;59(12 Suppl 6):S28-32. doi: 10.1212/wnl.59.12_suppl_6.s28.